



[12] Patent

[11] Patent No.: GC 0000175	Number of the Decision to Grant the Patent: 5/299
[45] Date of Publishing the Grant of the Patent: 29/03/2006 5/2006	Date of the Decision to Grant the Patent: 29/03/2005
[21] Application No.: GCC/P/1999/314 [22] Filing Date: 09/10/1999 [30] Priority: [31] Priority No. [32] Priority date [33] State 60/104,024 13/10/1998 US [72] Inventors: 1- Nancy Jane Harper, 2- Gautam Ramchandra Ranade, 3- Willard McKowan Welch [73] Owner: Pfizer Products Inc., Eastern Point Road, Groton, Connecticut 06340, USA [74] Agent: Nassir Ali Kadasa	[51] Int. Cl. ⁷ : A61K 31/135, 47/10 [56] Cited Documents: - EP 0030081 A (PFIZER) 10 June 1981 - CA 2143070 A (P. MODI) 23 August 1995 - EP 0768083 A (PFIZER) 16 April 1997 - EP 0415612 A (PFIZER) 06 March 1991 - WO 9901113 A (PFIZER) 14 January 1991

[54] SERTRALINE ORAL CONCENTRATE

[57] Abstract: The present invention provides an essentially nonaqueous, liquid pharmaceutical concentrate composition for oral administration containing sertraline or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable excipients. The present invention also provides a use of this concentrate composition to prepare an aqueous solution of sertraline. In addition, the present invention provides a method of using this concentrate composition to treat or prevent a variety of diseases or conditions. Finally, the present invention provides the compound, (1S-cis)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-naphthalenamine methanesulfonate.

No. of claims:13